巴基斯坦的Covid-19疫苗安全性和不良事件分析
Syed Shahzad Hasan1,2, Abdur Rashid3, Sundus Osama4
1Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, UK.
Clinical immunology communications
|November 28, 2023
概括
巴基斯坦接种了超过8400万剂COVID-19疫苗,大多数不良反应是轻度的,如发烧或注射部位疼痛. 总的来说,COVID-19疫苗耐受性良好,好处超过风险.
科学领域:
- 公共卫生 公共卫生
- 疫苗学 疫苗学 疫苗学
- 药物监督 药物监督 药物监督
背景情况:
- 巴基斯坦的COVID-19疫苗接种活动于2021年2月2日开始,利用多种疫苗.
- 截至2021年9月7日,已提供超过8400万剂疫苗,政府采购和国际援助为此做出了贡献.
- 在全国范围内建立了药监中心,以监测疫苗的安全性.
研究的目的:
- 分析在巴基斯坦使用的COVID-19疫苗的安全性.
- 报告和描述免疫接种后不良事件 (AEFI).
- 评估巴基斯坦人口中COVID-19疫苗接种的整体风险效益比.
主要方法:
- 数据来自国家免疫管理系统 (NIMS),COVIM,1166帮助电话和MedSafety.收集的数据.
- 分析了截至2021年9月30日报告的39,291起药物不良反应 (ADR).
- 国家AEFI审查委员会对24个严重的AEFI进行调查.
主要成果:
- 大多数AEFI在第一剂后和24-72小时内报告.
- 常见的AEFI包括发烧/发 (35%),注射部位疼痛/发红 (28%) 和头痛 (26%).
- AEFI报告率 (每1000剂量0.27-0.79) 低于英国,可能是由于报告不足.
结论:
- 在巴基斯坦,COVID-19疫苗的耐受性很好.
- 通过国家监督系统,没有发现任何重大安全问题.
- 巴基斯坦COVID-19疫苗接种的好处明显超过了风险.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
130
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
130
01:12Hazard Ratio
130
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
130